Colorado Marijuana Growers Vying for DEA Research Approval – Westword


Keep Westword Free

Support Us

I Support

  • Local
  • Community
  • Journalism

Two Colorado facilities believe they’re on track to become the first cultivators in the state to receive Drug Enforcement Administration approval for medical marijuana research purposes.

After waiting for years, NuVue Pharma and MedPharm Holdings are still chasing DEA approval to grow cannabis for federally sanctioned medical studies. MedPharm, already licensed by the City of Denver and State of Colorado to grow medical marijuana for research purposes, has been waiting since 2016 for a decision on its DEA application, according to CEO Albert Gutierrez.

Since 1968, the University of Mississippi had a monopoly on growing cannabis for federally recognized research, but the quality of the cannabis has been criticized by researchers. Application delays by former United States attorney general Jeff Sessions and the DEA slowed the process to license new growing operations for nearly four years before the Biden administration restarted application reviews in 2021. The DEA awarded a handful of research licenses in May and is expected to dole out more in the near future.

With a bigger research pool and more federal support for cannabis research, Gutierrez believes the long-overdue decision will help his company and others conduct better research on the efficacy of medical marijuana; he plans to study the plant’s effect on neuropharmacology and diseases like Parkinson’s, Alzheimer’s, dementia and traumatic brain injuries.

MedPharm is currently waiting on a final verdict from the DEA following some review recommendations by the agency, and the company expects to hear back soon based on the DEA’s May announcement.

“If we’re able to conduct research that articulates the medicinal value of cannabis, then we can go ahead with the findings, and that allows lawmakers to create better legislation around it,” Gutierrez says. “It’s been a long process. We’ve heard a lot of the anecdotal information, and now it’s time to apply that research.”

Unlike MedPharm, NuVue applied to become a cannabis bulk manufacturer with DEA, sending its first inquiry in 2019. According to NuVue CEO Katharine Avery, the lengthy process to apply included providing the DEA with several hundreds of pages of documentation

“They requested a lot of information from us. They look into the facility’s security, what vault will store the research-based cannabis,” she explains. “And they also look into the background of the company, including the owner and any individuals that will be in direct contact with the grow.”

Avery says NuVue, too, is waiting on a final review from the DEA with newly found optimism after May’s developments. The comany hopes to apply for a research growing license from the DEA in the future, she adds, and a supplying partnership with the Colorado State University-Pueblo Institute of Cannabis Research is in the works, as well. 

Keep Westword Free… Since we started Westword, it has been defined as the free, independent voice of Denver, and we would like to keep it that way. Offering our readers free access to incisive coverage of local news, food and culture. Producing stories on everything from political scandals to the hottest new bands, with gutsy reporting, stylish writing, and staffers who’ve won everything from the Society of Professional Journalists’ Sigma Delta Chi feature-writing award to the Casey Medal for Meritorious Journalism. But with local journalism’s existence under siege and advertising revenue setbacks having a larger impact, it is important now more than ever for us to rally support behind funding our local journalism. You can help by participating in our “I Support” membership program, allowing us to keep covering Denver with no paywalls.

Copyright © CSRA Science